Orchard Therapeutics Plc (ORTX) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Orchard Therapeutics Reports 2019 Financial Results and Reviews Key Strategic Priorities for 2020
February 27, 2020 7:01 AM ESTCommercial Preparations on Track for Potential Second Half 2020 EU Launch of OTL-200Â for MLD with U.S. Regulatory Filing Expected Late 2020 / Early 2021Â
Initiation of Rolling U.S. Regulatory Filing for OTL-101 (ADA-SCID) Planned for First Half 2020
Recent WORLD Presentations Showcased Data from Neurometabolic Franchise; Additional Clinical Data from MPS-I and MPS-IIIA Proof of Concept Trials Expected in 2020
$325M in Cash and Investments to Support Execution on Strategic Priorities in 2020 and Beyond
BOSTON and LONDON, Feb. 27, 2020 (GLOBE NEWSWIRE) --... More
